Funding
AMYOTROPHIC LATERAL SCLEROSIS
The study was supported by ARISLA (Fondazione Italiana di Ricerca per la SLA) (FGCR02/2015 to J.M.) and Pfizer Inc. (Pfizer provided the drug free of charge) (grant no. 53232941, program title: “Wi211892 Rapamycin treatment for Amyotrophic Lateral Sclerosis” to J.M.). The funders of the study were not involved in protocol design, data collection, statistical analysis, data interpretation, writing of the report and the decision to submit this article.